Attention Deficit Disorder
Conditions
Keywords
ADD, ADHD, attention deficit, hyperactivity
Brief summary
This is a placebo controlled study evaluating the efficacy and safety of medication in adults with Attention-Deficit Hyperactivity Disorder (ADHD).
Interventions
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Patient must be diagnosed with ADHD.
Exclusion criteria
* Patient has a current or past history of seizure disorder, brain injury, anorexia nervosa or bulimia. * Patient has a current diagnosis of Major Depressive Disorder (MDD). * Patient has a current primary diagnosis of, or received treatment for, Panic Disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD) or Acute Stress Disorder within the previous 12 months. * Patient has a lifetime diagnosis of bipolar disorder, schizophrenia or other psychotic disorders. * Patient has a positive urine test at screening for presence of illicit drugs or alcohol abuse during the past 12 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ADHD Rating Scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical Global Impressions -Severity and Improvement. | — |
| Quality of Life Enjoyment and Satisfaction Questionnaire. | — |
Countries
United States
Outcome results
None listed